Atlas Trials

Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma

Clinical trial NCT07472621 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07472621
Sponsor
Henan Cancer Hospital
Status
NOT_YET_RECRUITING
Study type
OBSERVATIONAL
DLBCL - Diffuse Large B Cell Lymphoma
Start date
2026-03-10
Primary completion
2027-03-07
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.